Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Claritas Pharmaceuticals Inc V.CLAS.H

Alternate Symbol(s):  CLAZF

Claritas Pharmaceuticals, Inc., formerly Kalytera Therapeutics Inc, is a biotechnology company that is focused on developing R-107 for the treatment of vaccine-resistant coronavirus disease (COVID) strains. The Company’s products in development include R-107 for coronavirus disease and Viral Infections, R-107 and Vaccines, and CLA-1816 for treatment of pain. R-107 is designed to defeat COVID viruses on contact. R-107 targets the Achilles heel of COVID, the spike protein on the surface of the virus. R-107 releases nitric oxide, which attaches to a specific amino acid on the spike protein, thereby disabling the spike protein. The CLA-1816 provides effective pain reduction, without the risks of addiction or respiratory suppression that exist with opioid analgesics. CLA-1816 strongly binds with and activates the alpha3 glycine pain receptor in the spine. The Company has leased a laboratory, office, and archival space in Beverly, Massachusetts.


TSXV:CLAS.H - Post by User

Post by Red~Oneon Mar 30, 2022 3:49pm
111 Views
Post# 34560291

RE:PHASE 1

RE:PHASE 1 Phase 1
The last and only time nitric oxide was approved (to treat newborn babies with respiratory failure) was in 1998 and that was to act as a smooth muscle relaxant (widen blood vessels in the lungs). Since 1998 there has been no approval for NO to treat a disease until this year. One Canadian company has done it, and no it is not CLAS..
Phase I studies of a new drug are usually the first that involve people. Phase I studies are done to find the highest dose of the new treatment that can be given safely without causing severe side effects.
Nitric Oxide is already known to have certain antimicrobial and health uses.
The problem, until now, has been how to administer it safely and cheaply.
Delivery systems using inhalation and other delivery mechanisms such as injection, inhalation and oral medication are now being developed.
The trick is to deliver the correct dose to the proper site with no neural or cellular toxicity. (cytotoxicity) Another issue is how to control the Nitric Oxide when it comes across a superoxide in the body and creates Peroxynitrite which can cause oxidative damage to biological tissues.
Salzman claims that R107 is safe and can be delivered effectively.
Other N.O. carriers are being developed to achieve this and that safe and accurate dosing is going to be key in Phase 1 clinical trials.


<< Previous
Bullboard Posts
Next >>